Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. We use our expertise in discovering, developing and patenting novel drug forms with improved physical properties, to develop new products in new indications that are differentiated from the original by way of: dosage, delivery route or presentation, thus creating new and attractive commercial opportunities.
| Executive Director: |
Daniel Gooding |
| Non-Executive Chairman: |
Julian Gilbert |
| Independent Non-Executive Director: |
Madeleine Kennedy |
| Address: |
6th Floor, 60 Gracechurch Street, London, United Kingdom |
| Phone: |
+44 (0)1223 627222 |
| Fax: |
|
| Website: |
https://nuformix.com/ |
| Email: |
|